SCHEMBL8488741

SCHEMBL8488741

c1coc(Cc2cnccn2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.49
TDP1 Q9NUW8 2/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
CYP1A2 P05177 5/20 0.42
CYP2D6 P10635 2/20 0.42
ADORA3 P0DMS8 2/20 0.41
ADORA2A P29274 2/20 0.41
ADORA2B P29275 2/20 0.41
ADORA1 P30542 2/20 0.41
MAPK1 P28482 3/20 0.40
KDM4A O75164 2/20 0.38
KDM5C P41229 2/20 0.38
KDM4E B2RXH2 1/20 0.38
KDM6B O15054 1/20 0.38
KDM4D Q6B0I6 1/20 0.38
KDM4C Q9H3R0 1/20 0.38
CYP3A4 P08684 4/20 0.38
CYP2C19 P33261 4/20 0.38
CLK4 Q9HAZ1 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11516114 0.81 ALDH1A1 (0.46) ALDH1A1TDP1MEN1KMT2ACYP1A2
SCHEMBL6129995 0.80 ALDH1A1 (0.52) ALDH1A1TDP1MEN1KMT2ACYP1A2
SCHEMBL13610488 0.78 TDP1 (0.43) ALDH1A1TDP1MEN1KMT2ACYP1A2
SCHEMBL6129993 0.77 ALDH1A1 (0.45) ALDH1A1TDP1MEN1KMT2ACYP1A2
SCHEMBL8834668 0.75 ALDH1A1 (0.41) ALDH1A1TDP1MEN1KMT2ACYP1A2
SCHEMBL1521573 0.73 HSP90AA1 (0.43) CYP1A2CYP2D6ADORA3KDM4ECYP3A4
SCHEMBL11184781 0.73 MAPK1 (0.48) ALDH1A1TDP1MEN1KMT2ACYP1A2
SCHEMBL4580145 0.72 ALDH1A1 (0.38) ALDH1A1TDP1MEN1KMT2ACYP1A2
SCHEMBL30665030 0.71 ALDH1A1 (0.46) ALDH1A1TDP1MEN1KMT2ACYP1A2
SCHEMBL4226888 0.71 ALDH1A1 (0.46) ALDH1A1TDP1MEN1KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6008224-A POTENT ENDOTHELIN ANTAGONISM TREATING VASOCONSTRICTIVE EFFECT AND CELL PROLIFERATION EFFECT KOWA CO., LTD. (JP) 1999-12-28 US claimed
US-20180132503-A1 PROCESS FOR PRODUCING A LIQUID EXTRACT, PROCESS FOR PRODUCING COFFEE WITH REDUCED BITTERNESS, PROCESS FOR PRODUCING TEA, AND PROCESS FOR PRODUCING A LIQUID EXTRACT WHICH INCLUDES PYRAZINES THE COCA-COLA COMPANY 2018-05-17 US disclosed
EP-3297450-A1 PROCESS FOR PRODUCING A LIQUID EXTRACT, PROCESS FOR PRODUCING COFFEE WITH REDUCED BITTERNESS, PROCESS FOR PRODUCING TEA, AND PROCESS FOR PRODUCING A LIQUID EXTRACT WHICH INCLUDE PYRAZINES The Coca-Cola Company (US) 2018-03-28 EP disclosed
WO-2016186686-A1 PROCESS FOR PRODUCING A LIQUID EXTRACT, PROCESS FOR PRODUCING COFFEE WITH REDUCED BITTERNESS, PROCESS FOR PRODUCING TEA, AND PROCESS FOR PRODUCING A LIQUID EXTRACT WHICH INCLUDE PYRAZINES THE COCA-COLA COMPANY (US) 2016-11-24 WO disclosed